AdipoGen Life Sciences

IL-2 (human) Superkine H9T (monomeric):Fc-KIH (human) (rec.)

CHF 440.00
In stock
AG-40B-0223-C01010 µgCHF 440.00
AG-40B-0223-30103 x 10 µgCHF 880.00
AG-40B-0223-C100100 µgCHF 1'800.00
More Information
Product Details
Synonyms IL-2 Superkine H9T (monomeric):Fc Knobs-into-Holes (human) (rec.); Interleukin-2; T Cell Growth Factor; TCGF; Aldesleukin; Super-2
Product Type Protein
Source/Host HEK 293 cells. Produced using animal component-free medium.

The extracellular domain of human IL-2 (aa 21-153) (mutant H9T containing the mutations of H9: L80F / R81D / L85V / I 86V / I92F and the new mutation Q126T) is fused at the C-terminus to the Fc portion of human IgG1 (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)).

Crossreactivity Human

Triggers greater antitumor responses by maintaining stem-cell memory phenotype of CD8+ T cells.


Binds to human and mouse IL-2R.

MW ~45kDa and 28kDa (SDS-PAGE)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.01EU/μg protein (LAL test).
Concentration After reconstitution:
for 10µg size: 0.1mg/ml
for 100µg size: 1mg/ml
Reconstitution Reconstitute with 100μl endotoxin-free water.
Formulation Lyophilized. Contains PBS.
Protein Negative Control

Fc-KIH (human) IgG1 Control (rec.) (Prod. No. AG-35B-0015)

Other Product Data

Uniprot link P60568 : IL-2 (human)
AfCS Signaling Gateway link A006222: IL-2 (mouse)

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability Stable for at least 6 months after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Interleukin-2 (IL-2) is a 133 amino acid glycoprotein with one intramolecular disulfide bond and variable glycosylation. It is secreted by activated T cells and induces proliferation and maturation of activated T cells, natural killer cells and lymphokine activated killer cells. IL-2 also stimulates proliferation of antibody-producing B cells, activates neutrophils and induces mononuclear cells to secrete IFN-γ and TNF-α and -β. Moreover, studies have shown that IL-2 is required for activation-induced apoptosis, an important homeostatic mechanism in the immune system, which is involved in the maintenance of peripheral tolerance to self-antigens.

IL-2 promotes T cell proliferation and particularly naive T cells. IL-2 signaling on activated T cells is effected through a quaternary high-affinity receptor complex consisting of IL-2, IL-2Rα (CD25), IL-2Rβ and IL-2Rγ. Naive T cells are relatively insensitive to IL-2 as they only express small amounts of IL-2Rβ and IL-2Rγ. They only acquire sensitivity after CD25 expression, which captures the cytokine and presents it to the IL-2Rβ and IL-2Rγ receptors. IL-2 Superkine (Fc) is an artificial variant of IL-2 called H9, containing mutations at positions L80F / R81D / L85V / I 86V / I92F. These mutations are located in the molecule's core that acts to stabilize the structure and to give it a receptor-binding conformation mimicking native IL-2 bound to CD25. These mutations effectively eliminate the functional requirement of IL-2 for CD25 expression and elicit proliferation of T cells. Compared to IL-2, the IL-2 superkine induces superior expansion of cytotoxic T cells, leading to improved anti-tumor responses in vivo, and elicits proportionally less toxicity by lowering the expansion of T-regulatory cells and reducing pulmonary oedema.

A new version of IL-2 Superkine with a new additional mutation called H9T reduces the binding of IL-2Rγ and promotes the expansion of CD8+ T cells without driving terminal differentiation. TCR-transgenic and chimeric antigen receptor-modified CD8+ T cells that are expanded with H9T showed stronger anti-tumor activity in vivo in mouse models of melanoma and acute lymphoblastic leukemia. The new variant of IL-2 called H9T, helps to maintain activated CD8+ T cells in a stem-cell-like state, with greater anti-tumor activity in two mouse models. Like IL-2 Superkine (H9), IL-2 Superkine (H9T) also works on human T cells.

The protein IL-2 Superkine H9T (monomeric):Fc-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IL-2 Superkine H9T:Fc Knobs sequence (synthesizing a protein of 45kDa) and one encoding for the Fc Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein IL-2 Superkine H9T (monomeric):Fc-KIH (human) (rec.).

InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

Product References
  1. An engineered IL-2 partial agonist promotes CD8+ T cell stemness: F. Mo, et al.; Nature 597, 544 (2021)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.